Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe

Phase 1CompletedNCT02029625

NVP Healthcare41 enrolled

Overview

The purpose of this study is to compare the pharmacokinetics of NVP-1205 and coadministration of rosuvastatin and ezetimibe.

rosuvastatin and ezetimibe(anti-dyslipidemia)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SCREENING

Masking

NONE

Enrollment

Conditions

Dyslipidemia

Interventions

NVP-1205DRUG

rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2

rosuvastatin and ezetimibeDRUG

coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2

Eligibility

Sex: MALEMin age: 19 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male subjects age between 19 and 55 signed informed consent Exclusion Criteria: * subjects have a history of allergy reaction of this drug or other drugs

Locations (1)

Kyungpook National Hospital

Jung-gu, Daegu, South Korea

Outcomes

Primary Outcomes

AUClast

Time frame: 0-96hr

Secondary Outcomes

AUCinf

Time frame: 0-96hr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.